Fluidigm to present state-of-the-art single-cell genomics technology, Nov. 8

The Fluidigm Corporation will be presenting on their single-cell genomics technology; an overview of the field of single-cell genomics and examples of applications on Friday, November 8 from 10 to 11 a.m. in Mac Hall 3189.

This technology is currently deployed in the lab of Dr. Lincoln Shenje of the Knight Cardiovascular Institute. This research capability is made possible by the generous donation from the Knight Family, and this is one of the numerous ways in which the Knight’s gift to the Knight Cardiovascular Institute and to the Knight Cancer Institute benefit the wider OHSU research community by bringing enhanced capabilities to OHSU.

About Fluidigm

Cells are as unique as the researchers who study them. Using single-cell genomics applications, researchers are able to identify differences between individual cells in a seemingly homogeneous population. Fluidigm has developed an entirely new approach to single-cell genomics based on microfluidic technology. Our innovative technologies enable highly parallel  transcriptome and targeted gene expression analysis from samples containing only a few hundred cells. By integrating and simplifying multiple steps in the single-cell workflow, you can rapidly and reliably isolate, process, and profile individual cells for multiple genomics applications.